Dermatologic therapy · 2016
The role of systemic steroids and phototherapy in the treatment of stable vitiligo: a randomized controlled trial.
Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El Mofty Medhat, Essmat Samia, Youssef Randa, Sobeih Sherine, Mahgoub Doaa, Ossama Sherine, Saad Akmal, El Tawdy Amira, Mashaly Heba M, Saney Iman, Helal Rana, Shaker Olfat
Аннотация
Pathogenesis of vitiligo is believed to be multifactorial disease with a wide variety of therapeutic modalities. The aim of this work is to assess the efficacy of oral mini-pulse steroids (OMP) plus Nb-U.V.B in comparison to OMP alone and Nb-U.V.B alone in treating stable vitiligo. A prospective randomized controlled study including 45 patients categorized into three groups receiving therapy for 3 months; Group A received Nb-U.V.B plus OMP, Group B received OMP alone while Group C received Nb-U.V.B alone. Clinical assessment and PCR evaluation of bFGF, ICAM1, and ELISA for AMA were done. Patients receiving Nb-U.V.B plus OMP and using Nb-U.V.B alone gave statistically significant clinical response than those treated with OMP alone. Statistically significant rise of BFGF was noticed after treatment with Nb-U.V.B plus OMP and with Nb-U.V.B alone. Patients treated with OMP alone and with Nb-U.V.B alone showed statistically significant drop of ICAM-1 after therapy. NB-U.V.B plus OMP and Nb-U.V.B alone were found to be clinically superior over OMP alone in treating stable vitiligo patients, hence suggesting that adding OMP to Nb-U.V.B can maintain clinical and laboratory success for a longer period of time and with less relapse.
Предметные рубрики MeSH
Administration, OralAdolescentAdultAgedAutoantibodiesCombined Modality TherapyEgyptFemaleFibroblast Growth Factor 2GlucocorticoidsHumansIntercellular Adhesion Molecule-1MaleMiddle AgedPrednisoneProspective StudiesPulse Therapy, DrugSkin PigmentationTime FactorsTreatment OutcomeUltraviolet TherapyVitiligoYoung Adult